Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013 (2013), Article ID 287696, 6 pages
http://dx.doi.org/10.1155/2013/287696
Research Article

A Retrospective Longitudinal Cohort Study of Antihypertensive Drug Use and New-Onset Diabetes in Taiwanese Patients

1Department of Pharmacy, China Medical University Hospital, Beikang Campus, Taichung 40402, Taiwan
2Institute of Pharmacy, China Medical University, Taichung 40402, Taiwan
3Department of Health Services Administration, China Medical University, Taichung 40402, Taiwan
4Central Region Branch, Bureau of National Health Insurance, Taichung 40709, Taiwan
5Yuan Rung Hospital, Changhua 51043, Taiwan
6Division of Internal Cardiology, Armed Forces Taichung General Hospital, and Basic Science, Central Taiwan University of Science and Technology, Taichung 41168, Taiwan

Received 27 August 2012; Revised 28 October 2012; Accepted 6 November 2012

Academic Editor: Joseph Fomusi Ndisang

Copyright © 2013 Ching-Ya Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Hu, P. Jousilahti, and J. Tuomilehto, “Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease,” European Heart Journal, vol. 28, no. 24, pp. 3059–3066, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Dall, S. E. Mann, Y. Zhang et al., “Economic costs of diabetes in the U.S. in 2007,” Diabetes Care, vol. 31, no. 3, pp. 596–615, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. E. Minshall, S. Roze, A. J. Palmer et al., “Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States,” Clinical Therapeutics, vol. 27, no. 6, pp. 940–950, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. I. McFarlane, A. Farag, and J. Sowers, “Calcium antagonists in patients with type 2 diabetes and hypertension,” Cardiovascular Drug Reviews, vol. 21, no. 2, pp. 105–118, 2003. View at Google Scholar · View at Scopus
  5. C. J. Pepine, E. M. Handberg, R. M. Cooper-DeHoff et al., “A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease the international verapamil-trandolapril study (INVEST): a randomized controlled trial,” Journal of the American Medical Association, vol. 290, no. 21, pp. 2805–2816, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. ALLHAT, “Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),” The Journal of the American Medical Association, vol. 288, no. 23, pp. 2981–2997, 2002. View at Google Scholar
  7. P. A. Morales, B. D. Mitchell, R. A. Valdez, H. P. Hazuda, M. P. Stern, and S. M. Haffner, “Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects: The San Antonio Heart Study,” Diabetes, vol. 42, no. 1, pp. 154–161, 1993. View at Google Scholar · View at Scopus
  8. U. Rajala, Q. Qiao, M. Laakso, and S. Keinänen-Kiukaanniemi, “Antihypertensive drugs as predictors of Type 2 diabetes among subjects with impaired glucose tolerance,” Diabetes Research and Clinical Practice, vol. 50, no. 3, pp. 231–239, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Weycker, J. Edelsberg, G. Vincze et al., “Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine,” Journal of Human Hypertension, vol. 21, no. 5, pp. 374–380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Ogihara, A. Fujimoto, K. Nakao, and T. Saruta, “ARB candesartan and CCB amlodipine in hypertensive patients: The CASE-J trial,” Expert Review of Cardiovascular Therapy, vol. 6, no. 9, pp. 1195–1201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. G. P. Jong, M. H. Chang, L. Tien et al., “Antihypertensive drugs and new-onset diabetes: a retrospective longitudinal cohort study,” Cardiovascular Therapeutics, vol. 27, no. 3, pp. 159–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. H. Karnes and R. M. Cooper-DeHoff, “Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects,” Expert Review of Cardiovascular Therapy, vol. 7, no. 6, pp. 689–702, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. G. T. McInnes, “The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors,” Journal of Human Hypertension, vol. 25, no. 6, pp. 343–345, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. W. J. Elliott, “Differential effects of antihypertensive drugs on new-onset diabetes?” Current Hypertension Reports, vol. 7, no. 4, pp. 249–256, 2005. View at Google Scholar · View at Scopus
  15. R. Padwal and A. Laupacis, “Antihypertensive therapy and incidence of type 2 diabetes: a systematic review,” Diabetes Care, vol. 27, no. 1, pp. 247–255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. E. N. Taylor, F. B. Hu, and G. C. Curhan, “Antihypertensive medications and the risk of incident type 2 diabetes,” Diabetes Care, vol. 29, no. 5, pp. 1065–1070, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. A. J. Scheen, “Renin-angiotensin system inhibition prevents type 2 diabetes mellitus—part 1: a meta-analysis of randomised clinical trials,” Diabetes and Metabolism, vol. 30, no. 6, pp. 487–496, 2004. View at Google Scholar · View at Scopus
  18. W. J. Elliott and P. M. Meyer, “Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis,” Lancet, vol. 369, no. 9557, pp. 201–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. J. Zillich, J. Garg, S. Basu, G. L. Bakris, and B. L. Carter, “Thiazide diuretics, potassium, and the development of diabetes: a quantitative review,” Hypertension, vol. 48, no. 2, pp. 219–224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. M. J. Bia and R. A. DeFronzo, “Extrarenal potassium homeostasis,” The American Journal of Physiology, vol. 238, no. 5, pp. E421–E427, 1980. View at Google Scholar · View at Scopus
  21. K. Fukao, K. Shimada, M. Hiki et al., “Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azeldipine and amlodipine on glucose tolerance and endothelial function–a crossover trial (AGENT),” Cardiovascular Diabetology, vol. 10, no. 79, pp. 1–7, 2011. View at Google Scholar
  22. R. Padwal, M. Mamdani, D. A. Alter et al., “Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort,” Diabetes Care, vol. 27, no. 10, pp. 2458–2463, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Dahlöf, R. B. Devereux, S. E. Kjeldsen et al., “Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol,” Lancet, vol. 359, no. 9311, pp. 995–1003, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. E. L. Gillespie, C. M. White, M. Kardas, M. Lindberg, and C. I. Coleman, “The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes,” Diabetes Care, vol. 28, no. 9, pp. 2261–2266, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Yusuf, J. B. Ostergren, H. C. Gerstein et al., “Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure,” Circulation, vol. 112, no. 1, pp. 48–53, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Bosch, S. Yusuf, H. C. Gerstein et al., “Effect of ramipril on the incidence of diabetes,” The New England Journal of Medicine, vol. 355, no. 15, pp. 1551–1562, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. J. I. Barzilay, P. Gao, L. Rydén et al., “Effects of telmisartan on glucose levels in people at high risk for cardiovascular dsease but free from diabetes: The TRANSCEND study,” Diabetes Care, vol. 34, no. 9, pp. 1902–1907, 2011. View at Google Scholar
  28. H. O. Lithell, “Hyperinsulinemia, insulin resistance, and the treatment of hypertension,” American Journal of Hypertension, vol. 9, no. 11, pp. 150S–154S, 1996. View at Publisher · View at Google Scholar · View at Scopus